Publications by authors named "Monika Ermann"

Claim this Profile
V
Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects.
Sara Canovas Nunes, Serena De Vita, Andrew Anighoro, François Autelitano, Edward Beaumont, Monika Ermann

Blood Cancer J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
Luke F Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann

Blood· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.
Doris Riether, Renee Zindell, Lifen Wu, Raj Betageri, James E Jenkins, Monika Ermann

Bioorg Med Chem Lett· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.
Eugene R Hickey, Renee Zindell, Pier F Cirillo, Lifen Wu, Monika Ermann

Bioorg Med Chem Lett· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.
Renée Zindell, Edward R Walker, John Scott, Patricia Amouzegh, Lifen Wu, Monika Ermann

Bioorg Med Chem Lett· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.
Doris Riether, Lifen Wu, Pier F Cirillo, Angela Berry, Edward R Walker, Monika Ermann

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Monika Ermann, Doris Riether, Edward R Walker, Innocent F Mushi, James E Jenkins

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, Christina Boucher, Lilly Chai, Monika Ermann

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, David C McGowan, David M Armistead, Monika Ermann

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solid-phase synthesis of imidazo[4,5-b]pyridin-2-ones and related urea derivatives by cyclative cleavage of a carbamate linkage.
Monika Ermann, Nadja M Simkovsky, Stanley M Roberts, David M Parry, Andy D Baxter

J Comb Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis